Norway
Hemispherian AS is a biotechnology company based in Norway, founded in 2015. Their mission is to develop new treatments for the most aggressive types of cancer, with a focus on creating a new drug to treat Glioblastoma Multiforme (GBM).
They aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients. The company recently secured a kr16.00M investment, in the form of a grant from the Norwegian Research Council on 15 December 2023.
Hemispherian's dedication to addressing critical medical needs through biotechnology places them at the forefront of innovation in the healthcare industry. With their focus on tackling challenging medical conditions and their recent financial backing, they are well-positioned to make a significant impact in the field of cancer treatment.
